Speaker

Ana Filipa Fonseca

Director - Global Radioligand Therapy ,Strategy & Early Portfolio, Novartis AG

Ana Filipa Fonseca, Director - Global Radioligand Therapy ,Strategy & Early Portfolio at Novartis AG, is speaking at 8th Targeted Radiopharmaceuticals Summit Europe 2026 (London, United Kingdom, 1–3 Dec 2026) in the session “From Scientific Promise to Commercial Reality: How Should the Industry Prioritise the Next Generation of Radioligand Therapy Opportunities?”.

Conferences: 1
Keynotes: 0
Upcoming: 1

Upcoming appearances

8th Targeted Radiopharmaceuticals Summit Europe 2026
1–3 Dec 2026London, United Kingdom
- SpeakerFrom Scientific Promise to Commercial Reality: How Should the Industry Prioritise the Next Generation of Radioligand Therapy Opportunities?

More speakers at 8th Targeted Radiopharmaceuticals Summit Europe 2026

Friedmund Bachmann
Vice President CMC & Project Lead, OncoOne
Luke Brzozowski
Executive Director - Translational Research & Core Facilities ,Program Sponsor, Theranostics, UHN
Frederic Desdouits
Chief Executive Officer, OranoMed
Chaitanya Divgi
Senior Expert - Strategic Therapeutic Innovation, Novartis
Kemp Dolliver
Director of Research, Brookline Capital Markets
Rich Edwards
Chief Technology Officer, Nuclide Therapeutics

See all 36 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Ana Filipa Fonseca, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].